On September 7, 2012, the Asian Fund for Cancer Research and the US Chinese Anti-Cancer Association(USCACA) jointly awarded five outstanding young Chinese cancer researchers the 2012 AFCR-USCACA Scholar Excellence Award.
Chinese researchers and physicians are being increasingly recognized in making significant contributions to advance biomedical researches including cancer research in China and the world. To facilitate and strengthen collaboration among cancer researchers and physicians in the United States and China, the US National Foundation for Cancer Research (US NFCR) and the US Chinese Anti-Cancer Association (USCACA) established the Scholar Excellence Award of the NFCR-USCACA Scholar Exchange and Fellowship Program in Basic, Translational, and Clinical Studies. Since 2010, five young Chinese researchers and physicians were awarded for their outstanding achievements in cancer research performed while they were in US, as well as their continuous contributions to eradicate human cancers after their return to China. This year, USCACA joined with the Asian Fund for Cancer Research, Ltd. (AFCR) selecting five outstanding young individuals to recognize and reward their research excellence in basic or clinical cancer research. Here, we are proud to introduce these five winners of the 2012 AFCR-USCACA Scholar Excellence Award:
Dr. Xiuli Bi at the College of Life Science, Liaoning University, Shenyang
Dr. Binghui Li at Laboratory of Cancer Cell Biology, Tianjin Medical University Cancer Institute and Hospital, Tianjin
Dr. Lina Zhang at the Department of breast cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin
Dr. Yi Zhang at the Department of Pharmacology at the College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu.
Dr. Yuhua Zhao at the Department of Biochemistry and Molecular Biology, Sichuan University, Chengdu, Sichuan
|The 2012 AFCR-USCACA Scholar Award Ceremony in Beijing on September 7, 2012|
These five awardees have been invited to contribute a short assay that summarizes their achievements in cancer research. As illustrated in their assays, these outstanding young scholars have received an excellent training under their mentors in US and made impressive discoveries in demonstrating mechanisms underlying the causes and progression of human cancers and in searching new approaches for improving treatments for cancer patients. The ultimate goal of the AFCR-USCACA Scholar Excellence Award is to expedite novel cancer drug development by stimulating the translation of lab discoveries to novel cancer treatments, fostering collaborations in clinical cancer drug development, and sharing best practices and knowledge between China and United States.
About the Asian Fund for Cancer Research
The Asian Fund for Cancer Research, Ltd. (AFCR) is a non-profit organization committed to curing cancers that have significant impacts on Asian populations. Established in 2005 and headquartered in Hong Kong, AFCR is uniquely positioned to implement in Asia the newest cancer research discoveries and technologies from around the world, investigate the distinct causes of cancer in Asian populations through innovative genetic and molecular research, and develop more effective therapies tailored to Asian cancer patients. AFCR is dedicated to bridging the scientific and educational gaps in cancer research and cancer prevention between Asian countries and the rest of the world through promoting, coordinating and funding international collaboration in cancer research and public education.
In recent years, as a newly established organization in Hong Kong, AFCR has provided funding to support cancer research projects in Hong Kong University and an Asia-focused cancer tissue bank program – the Tissue Bank Consortium in Asia (TBCA). AFCR is working proactively with our partners in China and in other Asia countries to built up a greater collaboration network at a higher academic level to reduce the incidence and increase the survival rate of cancers in Asia.
About the US Chinese Anti-Cancer Association
USCACA is a non-profit professional organization founded in 2009. With members from academia, industry and government, USCACA facilitates collaborations among cancer researchers and physicians in the United States and China. Our current focus is on expediting novel cancer drug development by fostering clinical trial networks, sharing best practices and knowledge of clinical trial, and providing education and training opportunities. USCACA collaborates with the Chinese Anti-Cancer Association (CACA), the Chinese Society for Clinical Oncology (CSCO), and other professional associations. Our mandate is to improve cancer treatment through research, education, and collaboration.
The Common Goal of AFCR and USCACA
The common goal of AFCR and USCACA is to improve our understanding of cancer and to provide more efficacious and safe treatment options to cancer patients through expediting novel cancer drug development by stimulating the translation of laboratory discoveries into novel cancer treatments, fostering collaborations in clinical cancer drug development, and sharing best practices and knowledge between China and the United States. The AFCR-USCACA Scholar Exchange and Fellowship Program provides a unique opportunity for young Chinese scholars who have an interest in advancing their basic, translational, and clinical knowledge and skills, and in establishing long-term collaborations with leading scientists in the United States who can support their continued work and future success in China.